Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2025)

Historic Long-Term Investments for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $28.0 million.

  • Indivior Pharmaceuticals' Long-Term Investments rose 769.23% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 769.23%. This contributed to the annual value of $27.0 million for FY2024, which is 3414.63% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Long-Term Investments stood at $28.0 million, which was up 769.23% from $27.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Long-Term Investments high stood at $98.0 million for Q4 2022, and its period low was $26.0 million during Q1 2024.
  • Its 4-year average for Long-Term Investments is $36.2 million, with a median of $27.0 million in 2024.
  • Its Long-Term Investments has fluctuated over the past 5 years, first plummeted by 5816.33% in 2023, then skyrocketed by 769.23% in 2025.
  • Indivior Pharmaceuticals' Long-Term Investments (Quarter) stood at $98.0 million in 2022, then plummeted by 58.16% to $41.0 million in 2023, then crashed by 34.15% to $27.0 million in 2024, then rose by 3.7% to $28.0 million in 2025.
  • Its Long-Term Investments was $28.0 million in Q3 2025, compared to $27.0 million in Q2 2025 and $27.0 million in Q1 2025.